Emgality is a calcitonin gene-related peptide (CGRP) binding antibody studied in migraine and episodic cluster headache1

Emgality is a humanized monoclonal antibody that binds to CGRP and blocks its binding to the receptor1

CGRP, Emgality, CGRP receptor and blood vessel

There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1

See how Emgality works

Discover the efficacy of Emgality for patients with migraine or episodic cluster headache

Reference: 1.Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.